Business Wire

Galderma, Nestlé Skin Health’s Medical Solutions Business, Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Jaa

Galderma, Nestlé Skin Health’s medical solutions business, today announced positive results from a Phase 2b dose-ranging study of nemolizumab in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. Nemolizumab, an investigational subcutaneous anti-IL-31 receptor A monoclonal antibody, met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared to placebo, and met secondary endpoints of major significance to Quality of Life improvement, such as Peak Pruritus Numerical Rating Scale (NRS) score vs. baseline for example.

These clinical data, coupled with previous phase 2a results from our licensing partner Chugai, support the growing scientific evidence that the IL31 pathway may be an important driver in atopic dermatitis. These results clearly support dose selection and will allow us to pursue the development as planned. We confirm our intent to progress nemolizumab into phase 3 in 2019 ” said Thibaud Portal, Ph.D., Vice President of Galderma’s Prescription business.

Atopic dermatitis is a chronic inflammatory skin disease, and is the most common form of eczema which frequently begins in childhood and can last through adulthood, although in some patients it may start in adulthood. Moderate-to-severe atopic dermatitis is characterized by an allergic response driven by a subset of immune cells called Type 2 helper T cells, or Th2 cells. IL-31, a cytokine released by Th2 cells, is involved in AD associated pruritus by interacting with IL-31 receptor alpha expressed by neurons, and is also thought to play a role in AD skin inflammation and AD skin barrier impairment. Moderate-to-severe forms of atopic dermatitis can be characterized by pronounced cutaneous dryness, and skin lesions marked by redness, infiltration/papulation, crusting/oozing, and lichenification, with periods of lesion exacerbation accompanied by intense itching, scratching, and skin damage that can lead to secondary infections. Moderate-to-severe atopic dermatitis can negatively impact patients’ lives and is associated with a high burden to patients particularly with itching, sleep deprivation and depression.

About Nemolizumab

Nemolizumab, a humanized monoclonal antibody, is directed against the IL-31R alpha, which blocks IL-31 signaling. Nemolizumab, initially developed by Chugai, was subsequently licensed to Nestlé Skin Health in 2016. Nemolizumab is an investigational agent under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.

About Galderma

Galderma, Nestlé Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com

Contact information

Media
Nestlé Skin Health
Sébastien Cros, Head of Corporate Communications
info@nestleskinhealth.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Hansard Global Plc Selects SaaS-Based Majesco LifePlus Solutions to Transform Their Business21.3.2019 23:30:00 EETTiedote

Majesco (NASDAQ:MJCO), a global leader of cloud core insurance software, today announced that Hansard Global plc, a FTSE listed business, selected Majesco Life IllustratePlus, Majesco Life AdminPlus, and Majesco Life DistributionPlus to support its ambitious growth plans. Hansard Global plc, which is headquartered on the Isle of Man, provides innovative financial products and services for financial advisors and their international clients, leveraging the latest technology to deliver an award-winning online proposition and best-in-class service. This is the third UK win announced in the last 12 months, following the launch of the SaaS offering in February of 2016 and has received a hugely positive response from the industry, endorsed by numerous industry awards. Majesco has established itself as a market leader in cloud-based core insurance solutions within the individual life and pensions sector. Ollie Byrne, Chief Strategy Officer at Hansard Global plc, commented “Our current system h

ResMed to Host an Investor Meeting on April 4, 201921.3.2019 23:05:00 EETTiedote

ResMed (NYSE: RMD) (ASX: RMD) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to respiratory care and out-of-hospital software. Additional information regarding the investor meeting, including the specific time and webcast link for the presentations, will be made available approximately one week prior to the event and may be accessed by visiting http://investor.resmed.com. Space for the event is limited and therefore in-person attendance is available by invitation only. Presentations at the investor meeting will be transmitted by a live webcast, which may be accessed by visiting http://investor.resmed.com. A replay of the webcast will be accessible on our website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible for approximately one year thereafter. Abo

KILL OnMiners Changing the Game in Cryptocurrency Mining21.3.2019 22:51:00 EETTiedote

Business Wire requests that NewsItemId: 20190318005779, OnMiners press release "OnMiners Changing the Game in Cryptocurrency Mining" issued March 18, 2019 be removed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005779/en/ View source version on businesswire.com: https://www.businesswire.com/news/home/20190318005779/en/ Contact information Business Wire, France +33 (0) 1 56 88 29 40

Her Excellency Sheikha Hind Attends International Universities Arabic Debating Championship Closing Ceremony21.3.2019 18:03:00 EETTiedote

Her Excellency Sheikha Hind bint Hamad Al Thani, Vice Chairperson and CEO of Qatar Foundation (QF), attended the closing ceremony of the fifth edition of the International Universities Arabic Debating Championship (IUDC) organized by QatarDebate, a member of QF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005482/en/ Princess Sumaya University for Technology in Jordan takes First Place (Photo: AETOSWire) The championship – held under the patronage of Her Excellency Sheikha Hind bint Hamad Al Thani – took place at Qatar National Convention Centre from March 16-20, 2019, and included 107 teams from 51 Arab and non-Arab countries. During the ceremony, Her Excellency Sheikha Hind presented the winners with their awards. The debate team from Princess Sumaya University for Technology in Jordan took first place in this year’s edition of IUDC. The boys’ team from Qatar University was awarded second place, while the team from

Taulia Enhances Platform with New Artificial Intelligence Capabilities in a World First for Working Capital Solutions21.3.2019 18:00:00 EETTiedote

Harnessing the latest developments in AI technology, Taulia’s upgraded platform supports simplified, informed decision-making and strengthens the buyer-supplier relationships. Taulia has upgraded its platform with a set of new world-class AI capabilities. Rate of suppliers taking advantage of early payment offers increases three fold. The enhanced platform supports companies in making better informed decisions about their working capital and cash. Working capital solutions provider, Taulia, has rolled out a new version of its buyer platform, bringing enhanced artificial intelligence (AI) capabilities to its programs. Companies now have the power of AI at their fingertips with the next-level enhancement of Taulia’s platform. The platform taps into aggregated data on supplier behavior, such as the historic timing of payments and the annual percentage rate (APR) accepted by suppliers when taking early payment, plus other factors including seasonality. By overlaying this with external data

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme